Shares of Sun Pharmaceutical Industries Ltd rose as much as 3.6 per cent in early trade and was the top percentage gainer on the NSE index.

Sun Pharma was the top gainer as the company has got an establishment inspection report (EIR) from the US health regulator for its Dadra facility.

"The receipt of EIR closes all outstanding inspections by the USFDA at the facility,'' the company said.

The stock hit its highest level since July 31 and led the gains on the Nifty Pharma index which was up 1.3 per cent.

This is positive from a compliance perspective given that Sun Pharma was able to resolve 11 observations in a shorter time, according to analysts at ICICI Securities.

The news provides confidence in potential resolution of the warning letter at Sun's key Halol facility that is awaiting re-inspection by the regulator, analysts add.

Sun Pharma's stock lost up to 30.4 per cent in the last 12 months up to Wednesday's close.